Biogen's study on BIIB080 shows potential for improving cognition in Alzheimer's patients, although it raises questions about the efficacy of higher doses. This research could influence future drug development strategies in tau-targeting therapies.
The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.
Original title: “Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs”